RxDoctor Payments Data

Osama Ismail, MD

Internal Medicine · Bonifay, FLNPI 1548794795

Payments from drug & device makers

$597in general payments, 2019–2025

Across 27 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$203
  • Melinta Therapeutics, LLC$51
  • GSK$45
  • AbbVie$40
  • Phathom Pharmaceuticals, Inc.$40
  • Vanda Pharmaceuticals Inc.$39
  • plus $178 from 8 others

What the payments were for

  • Food & beverage$597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$597 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,948
Medicare patients
74
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide124$129,431
HumiraAdalimumab12$83,496
FarxigaDapagliflozin Propanediol121$69,459
Breztri AerosphereBudesonide/Glycopyr/Formoterol88$56,481
EliquisApixaban109$55,209
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$43,579
JanuviaSitagliptin Phosphate73$43,285
MyrbetriqMirabegron93$37,368
MounjaroTirzepatide33$35,345
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl230$32,126
VraylarCariprazine Hcl21$31,972
Breo ElliptaFluticasone/Vilanterol73$30,463
XareltoRivaroxaban59$29,159
SymbicortBudesonide/Formoterol Fumarate123$28,023
TradjentaLinagliptin47$26,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$16$164,776157 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$203$153,962332 claims
AbbVieHumira, Vraylar, Namzaric, Linzess$40$140,488103 claims
GSKTrelegy Ellipta, Breo Ellipta$45$74,042140 claims
Indivior Inc.Suboxone$33$6,32213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bonifay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →